Raltegravir Plus Abacavir/Lamivudine: Effective HIV-1 Switch Therapy in Virologically Suppressed Patients
Raltegravir combined with abacavir/lamivudine is a safe and well tolerated switching strategy for patients with stable HIV-1 infection
Prednisone during the first month of ART for those with HIV leads to a lower incidence of tuberculosis-related immune reconstitution inflammatory syndrome.
Combination therapy of lamivudine plus dolutegravir has shown efficacy, safety, and tolerability in people with HIV-1 infection.
A new integrase inhibitors resistance pathway in HIV-2 infected patients has been identified rendering isolates that are highly resistant.